The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathway enrichment analysis in tumors with high mutation burdens and interferon-γ signature expression: A pancancer analysis.
 
Xuanyi Li
No Relationships to Disclose
 
Ben Ho Park
Leadership - Loxo
Stock and Other Ownership Interests - Celcuity; Loxo
Consulting or Advisory Role - Caris Life Sciences; Casdin Capital; Celcuity; EQRx; Guardant Health; Hologic; Horizon Discovery; Jackson Laboratory for Genomic Medicine; Janssen; Loxo; Sermonix Pharmaceuticals
Research Funding - Abbvie; GE Healthcare; Lilly; Pfizer
Patents, Royalties, Other Intellectual Property - Royalties paid through inventions at Johns Hopkins University by Horizon Discovery LTD
Travel, Accommodations, Expenses - Lilly; Loxo
(OPTIONAL) Uncompensated Relationships - Tempus
 
Justin M. Balko
Consulting or Advisory Role - AstraZeneca; Malinkrodt
Research Funding - Genentech/Roche; Incyte
Patents, Royalties, Other Intellectual Property - FCRL6 as an immunotherapy target; Patent on use of HLA-DR/MHC expression to predict response to immunotherapies; Patent pending on using peripheral blood gene signatures to predict response to chemotherapy in breast cancer (Inst)
Other Relationship - NanoString Technologies
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Catalyst Pharmaceuticals; Iovance Biotherapeutics; Mallinckrodt; Merck; Mosaic ImmunoEngineering; Novartis; Oncosec; Pfizer; Targovax
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy